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Abstract
Dengue is an important viral vector-borne disease worldwide. Its diagnosis requires laboratory confirmation
and the detection of dengue virus (DENV)-specific immunoglobulin (Ig) M by capture enzyme-linked
immunosorbent assay (ELISA) is a method frequently used. However, commercial kits of IgM-capture
ELISA for dengue diagnosis are expensive not easily available and obtain the results take long time in
endemic areas. Here, we aimed to standardize an in-house capture ELISA for the detection of DENV-
specific IgM in plasma for diagnosis of DENV infection. Plasma from two children with confirmed acute
DENV-2 infection was evaluated and two mouse monoclonal anti-DENV antibodies (one type-specific and
the other one serotype-cross-reactive) were tested. The assay was effective in the detection of DENV-
specific IgM in plasma and was comparable with a commercially available kit, even at the highest dilutions
of the sample and the mouse anti-DENV antibodies. Furthermore, in a child with primary DENV-2 infection,
plasma anti-DENV IgM was found to be serotype-specific. This work strengthens the technical capacity for
the study and diagnosis of DENV infection in an endemic area.
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Resumen
El dengue es una importante enfermedad transmitida por vectores a nivel mundial. Su diagnóstico re-
quiere confirmación por laboratorio. La detección de inmunoglobulina (Ig) M específica de virus dengue
(DENV) por ensayo de inmunoadsorción ligado a enzima (ELISA) es un método frecuentemente usado.
Sin embargo, las pruebas comerciales de ELISA de captura IgM para el diagnóstico de dengue son costo-
sos, no están fácilmente disponibles y la entrega de resultados toma más del tiempo que el deseado en
áreas endémicas. Aquí se propuso desarrollar una captura de ELISA para detección de IgM específica de
DENV en plasma y ayudar al diagnóstico de dengue. El plasma de dos niños con infección aguda por
DENV-2 confirmada y dos anticuerpos monoclonales anti-DENV hechos en ratón (uno serotipo-específico
y el otro de reacción cruzada para los 4 serotipos) fueron evaluados. El ensayo fue efectivo en la detección
de IgM específica de DENV y es comparable con un estuche comercialmente disponible, incluso a las
mayores diluciones de la muestra y de los anticuerpos anti-DENV. Adicionalmente, en un niño con infec-
ción primaria por DENV-2, la IgM específica de DENV en plasma fue serotipo-específica. Este trabajo
fortalece la capacidad tecnológica para el estudio y diagnóstico de la infección por DENV en un área
endémica.
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Introduction
Dengue is an important viral vector-borne disease, with an
annual prevalence of 390 million of infections, 96 million of
these symptomatic and 500,000 cases of clinically severe
forms(1). This disease is caused by any of four dengue virus
(DENV) serotypes (DENV-1, 2, 3 and 4), and it can clinically
range from asymptomatic to potentially life-threatening
disease, with shock, bleeding and organ dysfunction(2). The
diagnosis is based in clinical and laboratory criteria, the latter
including direct methods (detection of viral components such
as proteins and nucleic acids) and indirect methods (detection
of virus-specific immunoglobulins).
These assays are positive during different phases of
the disease, correlating with the early presence of the virus in
blood and the later induction of humoral immune response
(before and after the fourth day of beginning of the symptoms,
respectively)(3, 4). After the initial increase of DENV-specific
IgM during a primary infection, it remains detectable up to
three months (5).
The capture enzyme-linked immunosorbent assay
(ELISA) for the detection of DENV-specific IgM is frequently
used for dengue diagnosis, however commercial kits that use
this ELISA format are expensive and inaccessible in some
endemic areas, limiting the application of the assay for rapid
diagnosis of infection and for research and medical purposes.
To overcome this problem, some laboratories have designed
capture ELISAs for the detection of DENV-specific IgM, with
acceptable sensitivity and specificity(6,7). Therefore, the
development and implementation of these assays in highly
endemic areas would be essential for the diagnosis, in addition
to support local epidemiological and immunological studies.
Here, we standardized a semiquantitative capture ELISA for
the detection of DENV-specific IgM in plasma, which was
effective and could be a helpful tool to dengue studies when
combined with other direct and indirect methods.
Methods
Patients and samples. This study was approved by the
Ethics Committee of Universidad Surcolombiana and Hos-
pital Universitario of Neiva. Two children with acute DENV
infection were included according to WHO 2009 revised
guidelines(2). Infection was confirmed by detection of non-
structural protein (NS)-1 and/or DENV-specific IgM by
ELISA, and the infecting serotype was determined by
conventional reverse transcription polymerase chain
reaction (RT-PCR), as described below. Written parents
informed consent was obtained from each of the children
included. All experiments followed the principles expressed
in the Declaration of Helsinki. Socio-epidemiological
characteristics of the included children are shown in Table
1. Two to four milliliters of venous blood was collected in
tubes containing ethylenediaminetetraacetic acid (EDTA,
BD Vacutainer®; Ref: 367861). The tubes were centrifuged
at 300 x g, and the plasma was collected and stored at ?70ºC
until the time of analysis.
Viruses. DENV-1, 2, 3 and 4 were propagated in Vero-76
cells (acquired from ATCC, number CRL-1587D). Five hundred
µL of each serotype (kindly provided by Dr. Ivan Dario Velez,
Universidad de Antioquia, Colombia) were added to a Vero-
76 cells monolayer with a 70% confluence and they were
incubated in 1X DMEM medium with 2% fetal bovine serum
(both from GIBCO®, Carlsbad, CA; Cats: 11965-126 and 16000-
044, respectively) at 37ºC, 5% CO2. After 5 days culture, the
appearance of cytopathic effect on the cell monolayer was
checked by inverted light microscopy and the culture
supernatant (cell lysate) was collected, centrifuged and frozen
at -70°C until use. As control, cell lysate from uninfected cells
(mock) treated identically as described above was also
collected. The purity of each serotype was checked by RT-
PCR, as described below.
Mouse anti-DENV antibodies for capture ELISA. Two
anti-DENV antibodies were tested: mouse anti-E protein
antibody (clone 3H5.1, IgG1, immunogen: DENV-2; stock
concentration 1mg/mL; Millipore, Billerica, MA, Cat:
MAB8702) with reported specificity for DENV-2(8), and mouse
anti-DENV complex antibody (clone M8051125, IgG2a,
immunogen: DENV-4; stock concentration 1mg/mL; Fitzgerald,
Acton, MA, Cat: 10-D35), reported to be serotype-cross
reactive(9).
Detection and quantitation of DENV in cell lysate and
plasma by conventional RT-PCR and real time PCR.
Infecting serotypes in the analyzed plasma samples and cell
lysate were determined by RT-PCR and real time PCR,
respectively, as previously described (10, 11). The mean of the
number of copies/mL of DENV-2 ribonucleic acid (RNA) in
cell lysate was 4.9 x 10 (11), as we previously reported (10).
Commercial ELISA kits for diagnosis of DENV infection.
For the detection of DENV-specific IgM and IgG and viral
NS1 protein, Dengue IgM and IgG capture ELISA (Refs: E-
DEN01M and E-DEN02G, respectively) and Dengue Early
ELISA (Ref: E-DEN02P) were used (all from Panbio®, Alere,
Australia), following the manufacturer’s instructions and as
previously described(10). The type of infection (primary or
secondary) was determined by the DENV-specific IgM/IgG
ratio in plasma, taking a ratio ? 2 as a secondary infection, as
previously reported (12).
Capture ELISA for the detection of DENV-specific IgM.
Nunc MaxiSorp® flat-bottom 96 well plates (NUNC, Cat: 44-
2404-21) were coated with 70?L per well containing goat affinity
purified polyclonal F(ab’)2 fragment to Human IgM heavy
chains (KPL, Gaithersburg, MD, Cat:201-1003) at a
concentration of 2?g/mL in 1X Dulbecco’s phosphate-
buffered saline (DPBS, Gibco®, Carlsbad, CA; Ref: 14190-144),
pH 7.3, and incubated overnight at 4ºC. Then, the plates were
blocked for 1h at 37ºC with 150?L per well containing 5%
nonfat milk in 1X DPBS (Gibco®, Carlsbad, CA; Cat: 21600-
069) with 0.05% Tween 20 (ACROS, Geel, Belgium, Cat. 23336-
2500) (5% blocking solution). Seventy microliters per well of
plasma samples at specified dilutions in 2.5% blocking solution
and negative controls (2.5% blocking solution alone) were
added and incubated for 2h at 37ºC. Afterwards, plates were
washed four times with 0.1% Tween 20 in 1X PBS (wash bu-
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ffer) and 70?L per well containing the indicated DENV
serotype or mock cell lysate at a final dilution of 1/10 in 2.5%
blocking solution were added and the plate incubated for 1h
at 37ºC. Subsequently, plates were washed four times and
70?L per well containing mouse anti-DENV-2 antibody or
mouse anti-DENV complex antibody at concentrations of 10,
2 and 1?g/mL in 2.5% blocking solution were added and the
plates were incubated for 1h at 37ºC. Next, 70?L per well
containing biotin-labeled affinity purified goat anti-mouse IgG
antibody (KPL, Gaithersburg, MD, Cat: 16-18-02) and
horseradish peroxidase labeled streptavidin (KPL,
Gaithersburg, MD, Cat: 14-30-00), both at a final concentration
of 0.5?g/mL in 2.5% blocking solution, were added
respectively, each one being incubated for 1h at 37ºC. Finally,
plates were revealed with 70?L per well containing
tetramethylbenzidine 0.4g/L and 0.2% H2O2 (TMB, KPL,
Gaithersburg, MD, Cat: 50-76-00) and reaction was stopped
with 17.5?L per well containing 2M H2SO4 (MERCK,
Darmstadt, Germany, Cat: K38346532). Plates were read at
450nm in a Multiskan FC photometer (Thermo, Waltham, MA).
Dilutions with optical density double or higher than the
negative control and mock-treated wells were considered
positive.
Statistical analysis. GraphPad Prism® 6.0 (GraphPad
Software, La Jolla, CA) software was used for the statistical
analyses. Data are presented as mean and the respective stan-
dard deviations. Associations between variables were
determined with the Pearson test. A P value <0.05 was taken
as significant.
Results
Patients included. Two children of 7 and 168 months old
hospitalized at Departamento de Pediatría Hospital Universi-
tario of Neiva, Colombia, were included. Both cases were
clinically classified as severe dengue according to the revised
WHO guidelines, 2009(2). Venous blood samples were taken
on fourth day of fever. One patient presented primary
infection and the other one had secondary infection,
determined by DENV-specific IgM/IgG ratio as described in
methods section. Both patients were infected by DENV-2, as
determined by RT-PCR. The results of laboratory assays are
described in Table 1.
Determination of working concentration of mouse anti-
DENV antibodies. For the standardization of capture ELISA,
plasma from a child with secondary infection by DENV-2 was
used (as shown in Table 1). Previously optimized working
concentrations were used for F(ab’)2 fragment to Human IgM
heavy chains, biotin-labeled affinity purified goat anti-mouse
IgG antibody and horseradish peroxidase labeled
streptavidin(13), therefore only several concentrations of
mouse anti-DENV antibodies were evaluated. As shown in
the Figure 1, we assessed 10, 2 and 1µg/mL of mouse anti-
DENV-2 antibody and mouse anti-DENV complex antibody in
2.5% blocking solution, with previous addition of DENV-2 or
mock at a final dilution of 1/10 in 2.5% blocking solution. As
additional negative control, 2.5% blocking solution without
sample was added. As shown in the Figure 1, in comparison
with the mock and the negative control, at least the double of
optical densities (OD 450nm) were obtained when DENV-2
was added, and they were dose-dependent, with a strong
negative correlation between OD450nm and plasma dilutions
for all the concentrations of mouse monoclonal antibodies
tested (Pearson r=-1, P=0.01). The concentrations of anti-
DENV-2 antibody evaluated (clone 3H5.1) and anti-DENV
complex antibody (clone M8051125) showed similar OD450nm
dynamic (Figure 1A and 1B, respectively), therefore working
concentration of 1µg/mL was selected for further experiments.
In the Table 2 are depicted the OD450nm for each dilution and
the signal / background ratio. As expected, we confirmed that
anti-DENV complex antibody is cross-reactive (Figure 1B), as
its original immunogen was DENV-4 and here this monoclonal
antibody also was reactive against DENV-2. In summary,
efficient detection of DENV-specific IgM by capture ELISA
was obtained at high dilutions of anti-DENV antibodies, and
serotype-cross-reactivity of anti-DENV complex antibody was
confirmed.
Effectiveness of in-house DENV-specific IgM capture ELISA.
To test the efficiency in the detection of DENV-specific IgM
in plasma, the performance of our in-house assay and a
commercially available ELISA kit was compared on a plasma
dilution of 1/100. Consistent with commercial kit results, the
patients were also identified as DENV-specific IgM positive
when the in-house assay was used, both with mouse anti-
DENV2 antibody (clone 3H5.1) and mouse anti-DENV complex
monoclonal antibody (clone M8051125) (Figure 2).
Furthermore, comparable OD450nm signal / OD450nm back-
ground ratio was found between the assays (Figure 2).
Together, these results support an adequate performance of
the locally standardized assay.
DENV serotype-specific IgM was detected in primary
infection. The capture ELISA was effective in the detection
of DENV-specific IgM in secondary infection, and then we
Table 1. Results of serotyping and commercial ELISA
assays.
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Figure 1. Determination of working concentrations of mouse anti-DENV antibodies.
Different concentrations of mouse anti-DENV-2 antibody (clone 3H5.1) (A) and mouse anti-DENV complex monoclonal
antibody (clone M8051125) (B) were evaluated for the detection of DENV-specific IgM by capture ELISA. A plasma
sample from a child with confirmed secondary DENV-2 infection starting at 1/50 dilution in 2.5% blocking solution, was
serially two-fold diluted, as indicated. 2.5% blocking solution alone was used as negative control (dashed black lines).
10μg/mL (red lines), 2μg/mL (green lines) and 1μg/mL (blue lines) concentrations of mouse anti-DENV antibodies were
used after addition of DENV-2 (continuous lines) and mock (dashed lines). Pearson r and P value are shown for DENV-
2 treated wells.
Table 2. OD450nm and signal / noise ratio of the sample analyzed.
* OD450nm (signal / noise ratio). Mean OD450nm of the negative control = 0.057.
evaluated its performance in the detection of DENV-specific
IgM in plasma from a child with primary DENV-2 infection. In
this case, to test if IgM generated against DENV is serotype-
specific or cross-reactive, both DENV-2 and a DENV-1/4 mix
were used in the assay before the addition of mouse anti-
DENV antibodies at the optimized working concentration. As
shown in Figure 3, compared to the mock and the negative
control, at least the double of OD450nm were obtained when
plates were treated with DENV-2 but no with DENV-1/4 mix,
both in the presence of mouse anti-DENV2 antibody (clone
3H5.1) or mouse anti-DENV complex monoclonal antibody
(clone M8051125) (Figure 3A and B, respectively), with high
signal / noise ratios only when DENV-2 was the virus added
(Table 2), and there was a strong negative correlation between
OD450nm and plasma dilutions (Pearson r=-1, P=0.01). Thus,
plasma DENV-specific IgM from a child with primary DENV-2
infection bound preferentially to its currently infecting
serotype, and had low or no cross-reactivity to DENV-1 or 4.
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Figure 2. Comparable effectiveness of in-house DENV-
specific IgM capture ELISA with a commercially available
ELISA kit.
DENV-specific IgM in plasma (at a dilution of 1/100) from
two children with DENV-2 infection was detected with a
commercial DENV-specific IgM capture ELISA kit (as described
in methods section) and the in-house capture ELISA, using
the mouse anti-DENV-2 antibody (clone 3H5.1; 1μg/mL)
and mouse anti-DENV complex monoclonal antibody (clone
M8051125; 1μg/mL). The ratio of the OD450nm obtained
in the samples and negative controls in each assay
(OD450nm signal / OD450nm background ratio) is shown.
Mean and standard deviations are shown.
Discussion
Here we evaluated the performance of a capture ELISA for
the detection of DENV-specific IgM in plasma, both in primary
and secondary infections, showing to be effective. Moreover,
IgM in plasma from a child with primary infection was
serotype-specific.
For the standardization of the capture ELISA, a plasma
sample from a child with secondary infection by DENV-2 in
his fourth day of fever was used (Table 1), according to
previous reports which showed that DENV-specific IgM is
generated early in secondary infections(14). Although serum
is frequently used for serological assays, its use does not
allow cellular analyses for which anticoagulated blood is
required. Therefore, plasma was preferred over serum for our
standardization. Secondary mouse anti-DENV antibodies were
evaluated, as in this format of ELISA the detection of plasma
DENV-specific IgM depends on them. Indeed, the mouse anti-
DENV complex antibody (clone M8051125), with reported and
confirmed serotype-cross reactivity (Figure 1B), was included
to assess if IgM generated against DENV infection is type-
specific or serotype-cross-reactive.
Both mouse anti-DENV2 (type-specific) and mouse anti-
DENV complex antibody were evaluated at three
concentrations (10, 2 and 1µg/mL, Figure 1). One advantage
of this capture ELISA is that it is a semiquantitative assay.
Here, we used two-fold serial dilutions of plasma samples
and, in comparison with mock-treated wells and the negative
control, DENV-2-treated wells had higher OD450nm (at least
the double of the mock-treated wells and negative control)
even at the higher plasma dilution (1/800) (Figure 1), indicating
that in this assay probably the limiting titer of DENV-specific
IgM was not obtained, but suggests a good sensitivity
thereof. Moreover, at the lowest concentrations of monoclonal
antibodies (1µg/mL), both mouse anti-DENV antibodies
showed similar OD450nm than those of the highest
concentration (Figure 1), reason why this was selected for
this capture ELISA. Although we only used one plasma sample
to standardize the assay, the dose-effect response observed
after the serial dilutions supports our observations. Another
advantage of our indirect format is the flexibility in the use of
different detecting antibodies (in this case a biotin-labeled
goat anti-mouse IgG) and to avoid the decreased affinity of
secondary antibodies that can be induced after enzyme
conjugation (15).
The capability of the in-house capture ELISA for the
detection of DENV-specific IgM in plasma was compared with
a commercially available ELISA on a plasma dilution of 1/100,
which is recommended by this kit’s manufacturer. When the
performance of the in-house assay was evaluated qualitatively
(number of DENV-specific IgM positive or negative plasma
samples) and quantitatively (OD450nm signal / OD450nm
background ratio), it showed to be comparable to the
commercial kit (Figure 2), supporting its efficiency and
usefulness in dengue diagnosis. Of note, the anti-DENV
antibody in the Panbio® ELISA kit is a horseradish peroxidase
conjugated monoclonal antibody that is pre-mixed with DENV
antigens before the addition to the plate, but its reactivity is
not described by the manufacturer. However, as in our captu-
re ELISA a biotin-streptavidin detection system was used,
we expected to obtain higher OD450nm than the commercial
kit, which was not observed. The distinct reactivity and affinity
of the monoclonal antibodies here used could explain this
finding.
Based on the effectiveness obtained with this in-house
capture ELISA, we aimed to determine if plasma IgM generated
in a DENV primary infection could also be detected. Here we
showed that IgM in plasma from a child with confirmed primary
DENV-2 infection was preferentially serotype-specific, as only
DENV-2 but no DENV-1/4 mix-treated wells had higher
OD450nm in comparison with mock-treated wells and the
negative control (Figure 3). Previous reports have shown that,
during primary DENV infections, IgM is only reactive against
its corresponding infecting virus(16), but others have
described a lack of correlation between IgM responses and
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Figure 3. DENV serotype-specific IgM was detected in primary infection.
A plasma from a child with DENV-2 primary infection was evaluated for the detection of DENV-specific IgM by capture
ELISA using mouse anti-DENV2 antibody (clone 3H5.1) (A) and mouse anti-DENV complex monoclonal antibody (clone
M8051125) (B). The plasma was added at 1/50 dilution in 2.5% blocking solution, and two-fold serial dilutions were
performed, as indicated. 2.5% blocking solution alone was used as negative control (dashed black lines). Mouse anti-
DENV antibodies at a working concentration of 1μg/mL were used after addition of DENV-2 (continuous red lines),
DENV-1 and 4 (continuous blue lines) and mock (dashed green lines). Pearson r and P value are shown for DENV-2
treated wells.
the isolated virus serotype, even though the highest levels
were found against the infecting serotype(17, 18), then this
issue remains to be explored. The use of a previously known
cross-reactive mouse anti-DENV antibody which was
generated by immunization with DENV-4 (the serotype
included in this assay), a dose-response effect after dilution
of the sample and acceptable signal / noise ratios support our
results. Evidently, more samples have to be analyzed, including
a mix with all the DENV serotpyes, to confirm this finding and
to corroborate the performance of our ELISA protocol.
In summary, a semiquantitative in-house capture ELISA
for the detection of DENV-specific IgM was standardized,
and it showed to be effective and comparable with a
commercial kit in the measurement of IgM response during
primary and secondary infections in children. IgM generated
in primary infection was serotype-specific. The use of this
assay combined with other direct and indirect methods could
be helpful for the diagnosis and studies of virology and
immunology of dengue in endemic areas.
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